PCSA Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 142879 min ago

@ $2.43

Ausgestellt: 12 Feb 2024 @ 21:26

Rendite: -21.81%

Vorheriges Signal: Feb 6 - 20:26

Vorheriges Signal: Verkaufen

Rendite: 0.00 %

Live Chart Being Loaded With Signals

Commentary (21 Mai 2024 @ 22:00):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Tagesvolumen	41 591.00
Durchschnittsvolumen	1.48M
Marktkapitalisierung	5.43M
EPS	$0 ( 2024-05-20 )
Nächstes Ertragsdatum	( $-0.980 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.220
ATR14	$0.0170 (0.89%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.52
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Volumen Korrelation

Lang: -0.12 (neutral)

Kurz: -0.32 (neutral)

Signal:(49.291) Neutral

Processa Pharmaceuticals, Korrelation

10 Am meisten positiv korreliert
VTNR	0.928
UXIN	0.926
VRM	0.924
PLL	0.92
AXDX	0.912
RNAZ	0.91
CNSP	0.904
MHUA	0.897
IRBT	0.896
SNAX	0.893

10 Am meisten negativ korreliert
FFNW	-0.912
HQY	-0.886
ADTH	-0.881
SFBC	-0.875
FGFPP	-0.867
ISRG	-0.859
AGNCP	-0.854
FSEA	-0.849
PRAX	-0.847
SRPT	-0.845

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Processa Pharmaceuticals, Korrelation - Währung/Rohstoff

-0.81
( strong negative )

-0.76
( moderate negative )

0.00
( neutral )

-0.76
( moderate negative )

-0.66
( moderate negative )

0.67
( moderate )

Processa Pharmaceuticals, Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2023
Umsatz:	$0
Bruttogewinn:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2022
Umsatz:	$0
Bruttogewinn:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.